I / we must be missing something here.
Phase 2 complete raising CD34 by 1.5 times over 8 weeks (is that good enough for commercial viability or is this a positive indication where extended tests now required).
Is there a similar existing drug currently licensed potentially preventing the original application of ALT1102 to be registered (this may explain why partnerships not on the table.
What was the target market for MS treatment
With potential to license under ODA (due to other application with stem cells) would this mean both applications/vendors could now fast track through ODA or MS therapy still to be trialled via lengthy FDA process.
All of a sudden, ALT 1102 looks more promising than Alt1103 given efficacy / safety proven.
Why are we trading at this level???
- Forums
- ASX - By Stock
- atl1102 new stem cell mobilization indication
I / we must be missing something here. Phase 2 complete raising...
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M |
Open | High | Low | Value | Volume |
11.0¢ | 11.5¢ | 10.5¢ | $242.1K | 2.246M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 47453 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 278209 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 47453 | 0.105 |
8 | 487909 | 0.100 |
2 | 13179 | 0.099 |
1 | 13000 | 0.098 |
2 | 130927 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 278209 | 3 |
0.115 | 624832 | 7 |
0.120 | 380100 | 8 |
0.125 | 110429 | 2 |
0.130 | 85000 | 2 |
Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |